 mitomycin adjuv treatment gastric cancer follow-up seventi consecut patient two-arm random trial surgic resect advanc gastric cancer first arm patient control group treatment surgeri second arm patient adjuv chemotherapi consist mitomycin mmc week consecut cycl patient arm way year year patient control arm patient treatment arm dead relaps actuari surviv curv signific favor patient adjuv mmc year patient control arm patient treatment arm dead relaps statist differ actuari surviv curv favor treat patient advantag adjuv treatment stage frequent relaps site periton caviti relaps pattern special decreas liver metastas treat patient toxic acut mild delay toxic second malign data adjuv mmc surgeri gastric cancer success treatment effect evid year follow-up